EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Phenol (bio)isosteres in drug design and development

Calvin Dunker, Katja Schlegel, Anna Junker

Archiv der Pharmazie · 2025-01 · 358 (1)

DOI: 10.1002/ardp.202400700 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 24.11.2024. Verfasst von Calvin Dunker und 2 weiteren Autor:innen. Beteiligte Einrichtung: European Institute for Molecular Imaging (EIMI), University of Muenster, Muenster, Germany. Hauptthemen laut MEDLINE: Drug Design, Phenols, Drug Development. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, German Research Foundation (DFG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to their versatile properties, phenolic compounds are integral to various biologically active molecules, including many pharmaceuticals. However, their application in drug design is often hindered by issues such as poor oral bioavailability, rapid metabolism, and potential toxicity. This review explores the use of phenol bioisosteres–structurally similar compounds that can mimic the biological activity of phenols while potentially offering improved drug‐like properties. We provide an extensive analysis of various phenol bioisosteres, including benzimidazolones, benzoxazolones, indoles, quinolinones, and pyridones, highlighting their impact on the pharmacokinetic and pharmacodynamic profiles of drugs. Case studies illustrate the successful application of these bioisosteres in enhancing metabolic stability, receptor selectivity, and overall therapeutic efficacy. Additionally, the review addresses the challenges associated with phenol bioisosterism, such as maintaining potency and avoiding undesirable side effects. By offering a detailed examination of current strategies and potential future directions, this review serves as a valuable resource for medicinal chemists seeking to optimize phenolic scaffolds in drug development. The insights provided herein aim to facilitate the design of more effective and safer therapeutic agents through strategic bioisosteric modifications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignPhenolsDrug DevelopmentHumansAnimalsMolecular StructureStructure-Activity RelationshipBiological Availability

Stichwörter der Autor:innen

bioisosterdrug designpharmacokineticsphenolstructure‐activity relationships

Substanzen

Phenols

Autor:innen und Institutionen

  • European Institute for Molecular Imaging (EIMI), University of Muenster, Muenster, Germany.
  • Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • German Research Foundation (DFG)

Zitieren

APA

Dunker, C., Schlegel, K., & Junker, A. (2025). Phenol (bio)isosteres in drug design and development. Archiv der Pharmazie, 358(1). https://doi.org/10.1002/ardp.202400700

Vancouver

Dunker C, Schlegel K, Junker A. Phenol (bio)isosteres in drug design and development. Archiv der Pharmazie. 2025;358(1). doi:10.1002/ardp.202400700

BibTeX
@article{Dunker2025,
  author = {Dunker, Calvin and Schlegel, Katja and Junker, Anna},
  title = {Phenol (bio)isosteres in drug design and development},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {1},
  doi = {10.1002/ardp.202400700}
}
Kostenlos starten →